IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
19.42
+0.60 (3.19%)
May 27, 2025, 3:50 PM - Market open
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for IDEAYA Biosciences stock ranges from a low of $27 to a high of $68. The average analyst price target of $54.27 forecasts a 179.45% increase in the stock price over the next year.
Price Target: $54.27 (+179.45%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $63 → $66 | Buy | Maintains | $63 → $66 | +239.86% | May 22, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $50 | Buy | Reiterates | $50 | +157.47% | Feb 14, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $61 | Buy | Reiterates | $61 | +214.11% | Jan 15, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 17, 2024 |
Financial Forecast
Revenue This Year
11.79M
from 7.00M
Increased by 68.39%
Revenue Next Year
50.04M
from 11.79M
Increased by 324.54%
EPS This Year
-3.16
from -3.36
EPS Next Year
-3.07
from -3.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 35.9M | 183.2M | 225.2M | ||
| Avg | 11.8M | 50.0M | 168.9M | ||
| Low | n/a | 6.0M | 131.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 413.0% | 1,454.2% | 350.1% | ||
| Avg | 68.4% | 324.5% | 237.6% | ||
| Low | - | -49.3% | 162.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.13 | -2.45 | -1.47 | ||
| Avg | -3.16 | -3.07 | -2.39 | ||
| Low | -3.62 | -4.00 | -3.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.